New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 15, 2014
07:34 EDTFSLR, VRTXStocks with call strike movement; VRTX FSLR
Vertex (VRTX) May 92.5 call option implied volatility increased 6% to 61, First Solar (FSLR) June 62.5 call option implied volatility increased 4% to 61 according to IVolatility.
News For VRTX;FSLR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2015
07:09 EDTVRTXVertex, Novavax among select biotechs to buy on weakness, says Piper Jaffray
Subscribe for More Information
August 25, 2015
11:41 EDTFSLRSolarCity rises again after Chairman Musk buys shares
Subscribe for More Information
August 24, 2015
16:46 EDTFSLRPresident Obama announces new renewable energy commitments
Subscribe for More Information
13:36 EDTVRTXBiotech correction presents some opportunities, says RBC Capital
RBC Capital analyst Michael Yee said he won't try to pick the short-term bottom in biotech, but contends that any macro weakness in China shouldn't have any major impact to financials or fundamentals for the sector given their minimal exposure there. If the market continues to be volatile, Yee recommends a focus on names with defensive characteristics, such as higher margins and free cash flow yield, naming Amgen (AMGN), Celgene (CELG) and Gilead (GILD) as some examples. The analyst adds that he likes Vertex (VRTX) on the pullback for "more aggressive" growth investors. Yee has Outperform ratings on all of the stocks mentioned above.
11:09 EDTFSLRGoldman says SolarCity attractive after sharp pullback
SolarCity (SCTY) shares are climbing in the down market after Goldman Sachs contended in a note to investors today that the stock is attractive following its recent sharp retreat, The company probably won't be affected by issues that are causing investors to worry about the solar sector, the firm believes. WHAT'S NEW: Noting that SolarCity's stock had tumbled 27% in the last month before today's open, Goldman Sachs analyst Brian Lee wrote that the shares are being dragged down by worries about financing and cost of capital that are affecting the entire solar sector. However, he contended that these issues are having only a "limited" impact on SolarCity. On August 13, the company successfully sold asset-backed securities and it said that more such sales are likely to occur in the near-term, Lee noted. Meanwhile, SolarCity isn't being affected by the cost of capital increases that other solar companies are experiencing, the analyst reported. Before today's open, the stock was near a two year low, even though SolarCity's fundamentals are still "strong," Lee believes. Additionally, the largest U.S. solar trade show, which is expected to begin on September 14, could boost solar stocks, as it has historically been a catalyst for the sector, the analyst stated. SolarCity may provide guidance about the outlook for its Silevo solar panel manufacturing subsidiary in the second half of 2015, and the guidance could boost the stock, Lee believes. The risk/reward ratio of SolarCity's stock is positive, according to the analyst, who has a Conviction List Buy and $85 price target on the shares. OTHERS TO WATCH: Other publicly traded companies in the solar space include Canadian Solar (CSIQ), First Solar (FSLR), JA Solar (JASO), SunEdison (SUNE), SunPower (SPWR), Trina Solar (TSL) and Yingli Green Energy (YGE). PRICE ACTION: In late morning trading, SolarCity advanced 5.3% to $43.18.
August 21, 2015
06:56 EDTFSLRSolar companies spending $1B in Texas projects, WSJ says
Subscribe for More Information
August 19, 2015
13:11 EDTFSLRCanadian Solar plummets after Q3 guidance, YieldCo comments
Subscribe for More Information
August 18, 2015
11:03 EDTFSLRSunEdison raises capital while Trina Solar tops expectations
Subscribe for More Information
August 17, 2015
06:22 EDTVRTXPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use